HOSPITAL UNIVERSITARIO RUBER
Departamento
![Foto de HOSPITAL UNIVERSITARIO RUBER](/img/noimage.png)
![Foto de Massachusetts General Hospital](/img/noimage_org.png)
Massachusetts General Hospital
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Massachusetts General Hospital (10)
2023
-
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management
International Journal of Dermatology, Vol. 62, Núm. 8, pp. 1020-1025
-
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659
-
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
Breast Cancer Research and Treatment, Vol. 201, Núm. 1, pp. 43-56
-
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Nature Reviews Clinical Oncology, Vol. 20, Núm. 6, pp. 372-389
2022
-
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
CA Cancer Journal for Clinicians, Vol. 72, Núm. 2, pp. 165-182
2021
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2019
-
Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Annals of Oncology, Vol. 30, Núm. 3, pp. 365-373
2017
-
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
Breast Cancer Research and Treatment, Vol. 163, Núm. 3, pp. 535-544
2015
-
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Nature Genetics, Vol. 47, Núm. 3, pp. 250-256
2012
-
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis
Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137